The stock price of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) has dropped by -0.67 compared to previous close of 8.90. Despite this, the company has seen a fall of -6.75% in its stock price over the last five trading days. zacks.com reported 2024-10-30 that The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Monte Rosa Therapeutics (GLUE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is It Worth Investing in Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Right Now?
GLUE has 36-month beta value of 1.30. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GLUE is 46.13M, and currently, short sellers hold a 11.34% ratio of that float. The average trading volume of GLUE on November 05, 2024 was 1.95M shares.
GLUE’s Market Performance
GLUE’s stock has seen a -6.75% decrease for the week, with a 73.67% rise in the past month and a 126.67% gain in the past quarter. The volatility ratio for the week is 9.99%, and the volatility levels for the past 30 days are at 11.45% for Monte Rosa Therapeutics Inc The simple moving average for the past 20 days is 40.52% for GLUE’s stock, with a 63.62% simple moving average for the past 200 days.
Analysts’ Opinion of GLUE
Many brokerage firms have already submitted their reports for GLUE stocks, with Wedbush repeating the rating for GLUE by listing it as a “Outperform.” The predicted price for GLUE in the upcoming period, according to Wedbush is $11 based on the research report published on February 15, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see GLUE reach a price target of $18. The rating they have provided for GLUE stocks is “Overweight” according to the report published on January 03rd, 2023.
UBS gave a rating of “Buy” to GLUE, setting the target price at $22 in the report published on October 13th of the previous year.
GLUE Trading at 46.69% from the 50-Day Moving Average
After a stumble in the market that brought GLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.71% of loss for the given period.
Volatility was left at 11.45%, however, over the last 30 days, the volatility rate increased by 9.99%, as shares surge +74.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +39.65% upper at present.
During the last 5 trading sessions, GLUE fell by -6.75%, which changed the moving average for the period of 200-days by +75.05% in comparison to the 20-day moving average, which settled at $6.29. In addition, Monte Rosa Therapeutics Inc saw 56.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GLUE starting from Versant Venture Capital VI, L., who sale 89,990 shares at the price of $9.66 back on Oct 28 ’24. After this action, Versant Venture Capital VI, L. now owns 2,007,948 shares of Monte Rosa Therapeutics Inc, valued at $869,240 using the latest closing price.
Versant Venture Capital VI, L., the 10% Owner of Monte Rosa Therapeutics Inc, sale 67,905 shares at $9.16 during a trade that took place back on Oct 29 ’24, which means that Versant Venture Capital VI, L. is holding 1,573,453 shares at $621,801 based on the most recent closing price.
Stock Fundamentals for GLUE
Current profitability levels for the company are sitting at:
- -9.61 for the present operating margin
- 0.47 for the gross margin
The net margin for Monte Rosa Therapeutics Inc stands at -8.99. The total capital return value is set at -0.46. Equity return is now at value -59.51, with -41.88 for asset returns.
Based on Monte Rosa Therapeutics Inc (GLUE), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -1.38. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -149.11.
Currently, EBITDA for the company is -137.09 million with net debt to EBITDA at 0.48. When we switch over and look at the enterprise to sales, we see a ratio of 32.94. The receivables turnover for the company is 1.47for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.56.
Conclusion
To put it simply, Monte Rosa Therapeutics Inc (GLUE) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
